Minimal Residual Disease in Solid Malignancies (IMRD)

European Institute of Oncology

Status

Not yet enrolling

Conditions

Breast Cancer

Gastric Cancer

High Grade Serous Ovarian Cancer

Non Small Cell Lung Cancer

Prostate Cancer

Treatments

Biological: ctDNA detection

Study type

Interventional

Funder types

Other

Identifiers

NCT07268469

UID 5046

L2-397 (Other Identifier)

Details and patient eligibility

About

The IMRD study is a single-centre, prospective observational study which will investigate the rate of ctDNA (circulating tumor DNA) detection from the start of adjuvant therapy following curative-intent surgery. The study will include patients of age 18 years old or older, who provided informed consent. Eligible patients are affected by one of the following non-metastatic resected tumors: i) breast cancer (BC), ii) non-oncogene addicted (EGFR/ALK-wild type) non-small-cell lung cancer (NSCLC), iii) high-risk and very high-risk prostate cancer, iv) high-grade serous ovarian cancer (HGSOC), and v) gastric cancer. Eligible patients will undergo surgery and receive adjuvant treatment(s) as per standard guidelines. Patients who underwent neoadjuvant treatments and had a complete pathological response (i.e., no residual tumor at surgery following neoadjuvant treatments) will not be eligible for the present study.

During adjuvant treatment and following its conclusion, patients will be subjected to instrumental monitoring, as per standard guidelines and clinical practice. For eligible patients, a baseline plasma sample will be collected at the time of surgery (feasibility window) and prior to the start of adjuvant treatments (not prior to 28 from the date of surgery) for assessing the detection of ctDNA. Afterwards, plasma samples will be collected at 3, 6 and 9 months from the start of postoperative adjuvant treatments. For patient specific monitoring, a tumor-informed targeted sequencing panel, using tumor-specific mutations detected with WES, will be employed to gather the most sensitive diagnostic platforms, mitigating the risk of negative cases. At 6 months or upon positive ctDNA detection, either a thoracic-abdominal-pelvic or total-body CT scan will be performed to exclude the presence of overt metastatic disease. All patients included in the study will be monitored with longitudinal ctDNA assessment until one-year or follow-up or until the radiological detection of metastatic disease, whichever will occur first. Additional follow-up will be carried outside the IMRD study and will follow standard clinical protocols and schedules. Being an observational study, no treatment intervention will be applied as per protocol based on the detection or absence of ctDNA. For conducting exploratory analyses, the primary tumors will be retrieved and subjected to WES, and the study will aim to detect molecular tumor variables associated with a lack of ctDNA clearance following curative-intent treatment interventions.

The study will be conducted in 2 phases. The first phase aims at verifying the feasibility and sustainability of such approach, based on the identification of at least 15% positive patients. This phase is predicted to be completed within 2 years, and is the object of the present application. If the first endpoint is achieved, we will expand the study to include the co-primary endpoint, which aims at estimating the fraction of patients with persistent ctDNA 6 months post-surgery despite adjuvant therapy.

Enrollment

840 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Provision of informed consent
Age ≥18 years
Eligibility for potentially-curative surgery, regardless of previous neoadjuvant/pre-operative systemic treatment
Completed adequate pre-surgical staging procedures as per standard clinical practice
Diagnosis of one of the following:
Clinical Stage II or III breast cancer
Clinical Stage II or III NSCLC
HGSOC, either relapsed after primary treatment, confirmed by biopsy, or suspected on the basis of radiological criteria
Prostate cancer, with at least one of the following: Gleason Score ≥8, radiologically ≥cT2c, or PSA >10
Gastric cancer with at least one of the following: Radiological/ecoendoscopic/laparoscopic evidence of node-positive disease, infiltration of the serosa or the surrounding organs, diffuse subtype as histology.

Exclusion criteria

Unable to provide informed consent
Unable to undergo surgery
Radiological evidence of metastatic disease
Unwilling to be subjected to longitudinal plasma samples collection
Prior diagnosis of a malignant tumor for which the patients underwent any type of anti-neoplastic treatment within 2 years prior to the study screening